September 26, 2020

Volume X, Number 270

September 25, 2020

Subscribe to Latest Legal News and Analysis

September 24, 2020

Subscribe to Latest Legal News and Analysis

September 23, 2020

Subscribe to Latest Legal News and Analysis

FDA Temporarily Relaxes Policies Relating to Eggs Produced for and Sold in the Retail Market

The COVID-19 pandemic has resulted in an increased consumer demand for shell eggs in the retail market and a reduced demand for further processed eggs. In response, and in order to facilitate the distribution of shell eggs to the retail market, the FDA has issued a pair of guidance documents that (i) relax food labelling requirements applicable to shell eggs and (ii) relax enforcement of the Egg Safety Rule (21 CFR Part 118).

The first of these guidance documents, issued on April 3, 2020, was directed to retail sellers of shell eggs and stated that the FDA would not object to the sale of shell eggs in cartons or flats that lack labels, provided that at the point of purchase no nutrition claims are made and the retailer displays in clear product-specific labeling:

  • a statement of identity;
  • the name and place of business of the manufacturer, packer, or distributor; and
  • safe handling instructions for shell eggs that have not been processed to destroy Salmonella Enteritidis (SE).

The second guidance document, issued on April 6, 2020, allows egg producers flexibility in compliance with the Egg Safety Rule when sending their eggs to the retail market. In particular, the guidance details modified requirements for compliance with the Egg Safety Rule for both poultry houses that are currently sending eggs to the retail market, and therefore would otherwise subject to more extensive regulation under the Egg Safety Rule, and for poultry houses that are not currently providing eggs to the retail market, and therefore would otherwise be subject to less extensive regulation under the Egg Safety Rule.

These recent guidance documents follow the FDA’s relaxation of food labeling requirements for restaurants and food manufacturers seeking to repurpose their food for retail sale (blogged about here) and the relaxation of nutrition information requirements in chain restaurants (blogged about here), and are yet another effort by the FDA to give the food industry flexibility as it adjusts to the changing market dynamics brought about by the pandemic. Keller and Heckman will continue to monitor and report on COVID-19 related developments that impact the food industry.

© 2020 Keller and Heckman LLPNational Law Review, Volume X, Number 98


About this Author

Keller and Heckman offers global food and drug services to its clients. Our comprehensive and extensive food and drug practice is one of the largest in the world. We promote, protect, and defend products made by the spectrum of industries regulated by the U.S. Food and Drug Administration (FDA), the European Commission and Member States authorities in the European Union (EU) and similar authorities throughout the world. The products we help get to market include foods, pharmaceuticals, medical devices, veterinary products, dietary supplements, and cosmetics. In addition...